Understanding the Market | CRO concept stocks continue to rise, WuXi AppTec makes progress in legal matters, benefiting CXO companies in securing new orders overseas

Zhitong
2026.08.11 03:51

CRO concept stocks continue to rise. As of the time of writing, Pharmaron (03759) is up 9.61%, trading at HKD 30.1; Genscript Bio (01548) is up 8.44%, trading at HKD 26.2; Asymchem (06821) is up 4.83%, trading at HKD 130.3; WuXi AppTec (02359) is up 2.22%, trading at HKD 202.4. On the news front, the CRO industry has recently welcomed multiple favorable developments. The U.S. released July non-farm employment data, showing a decrease of 23,000 jobs, significantly lower than the market expectation of an increase of 80,000 jobs. WuXi AppTec's legal progress: the execution of the U.S. Department of Defense's 1260H designation against the company has been suspended. WuXi AppTec, Beigene, and other leading companies in the pharmaceutical industry reported significant growth in their interim results. Guoyuan International pointed out that the probability of U.S. interest rate hikes is declining, overseas financing is fully recovering, and external demand is significantly improving. The legal progress of WuXi AppTec is beneficial for CXO companies to secure new orders overseas. The continuous exceeding expectations of Chinese innovative drugs going abroad fully validates the global competitiveness of Chinese innovative drug assets. We are firmly optimistic about the industry prospects of the innovative drug supply chain and recommend paying attention to companies with globally competitive innovative drug pipelines and significant business development landing or expectations, as well as CXO companies with rapid performance growth

According to Zhitong Finance APP, CRO concept stocks continue to rise. As of the time of writing, Pharmaron (03759) is up 9.61%, trading at HKD 30.1; Genscript Bio (01548) is up 8.44%, trading at HKD 26.2; Asymchem (06821) is up 4.83%, trading at HKD 130.3; WuXi AppTec (02359) is up 2.22%, trading at HKD 202.4.

On the news front, the CRO industry has recently welcomed multiple favorable developments. The United States released its non-farm payroll data for July, showing a decrease of 23,000 jobs, significantly lower than the market expectation of an increase of 80,000 jobs. WuXi AppTec's legal progress: the execution of the 1260H designation by the U.S. Department of Defense against the company has been suspended. WuXi AppTec, Beigene, and other leading companies in the pharmaceutical industry reported significant growth in their interim results.

Guoyuan International pointed out that the probability of interest rate hikes in the U.S. is declining, overseas financing is fully recovering, and external demand is showing significant improvement. The legal progress of WuXi AppTec is beneficial for CXO companies to secure new orders overseas. The continuous exceeding expectations of Chinese innovative drugs going abroad fully validates the global competitiveness of Chinese innovative drug assets. We are firmly optimistic about the industry prospects of the innovative drug supply chain and recommend paying attention to companies with globally competitive innovative drug pipelines and significant business development landing or expectations, as well as CXO companies with rapid performance growth

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.